Available at https://journalenrichment.com/index.php/jr/

Enrichment: Journal of Multidisciplinary Research and Development

Bench-to-bedside Strategies for Osteoporotic Fractures : A Systematic Literature Review

Yodha Bakti Rakha Astagina
Universitas Islam Sultan Agung Semarang, Indonesia
*Email: yodhabaktir@gmail.com

ARTICLE INFO

Keywords:
Bench-to-bedside, Fractures, Osteoporotic

ABSTRACT

Osteoporotic fractures represent a significant global health burden, particularly among aging populations. The purpose of this study is bench-to-bedside strategies for preventing and treating osteoporotic fractures through systematics reviews from various sources. A systematic review on clinical interventions for preventing and treating osteoporotic fractures typically employs a rigorous methodology to synthesize and analyze existing research. The process begins with a comprehensive literature search across multiple databases, including PubMed, Cochrane Library, EMBASE, and Web of Science. Bench-to-bedside strategies for osteoporotic fractures have resulted in substantial advances in the understanding, prevention, and management of this condition. The integration of basic scientific discoveries with clinical applications has resulted in better diagnostic tools, more effective therapies, and improved treatment models. These novel strategies represent a multidisciplinary approach to tackling osteoporotic fractures. By combining advanced diagnostics, targeted therapeutics, and personalized interventions, the bench-to-bedside pipeline aims to significantly reduce fracture incidence and improve patient outcomes.

INTRODUCTION

Osteoporosis is one of the significant public health problems worldwide, especially in countries with aging populations (Gregson et al., 2022). Various literature proves that this disease is characterized by decreased bone mass (Riggs BL & Melton LJ III, 1995) and damage to the microarchitecture of bone tissue, resulting in an increased risk of fractures (Chang & Lee, 2019). Osteoporotic fractures, especially those that occur in the hip bones, vertebrae, and wrists, can lead to significant morbidity, decreased quality of life, and even death in the elderly population (Sulima et al., 2023)

Osteoporotic fractures represent a significant global health burden, particularly among aging populations. These fractures, characterized by low bone mass and structural deterioration of bone tissue, lead to increased fragility and susceptibility to fractures (Abtahi et al., 2022). The journey from bench to bedside in osteoporosis research has been marked by significant advancements in understanding the underlying mechanisms of bone loss and the development of targeted interventions. Recent years have witnessed a surge in innovative clinical strategies aimed at both preventing and treating osteoporotic fractures (Huang et al., 2023). These approaches encompass a wide spectrum of interventions, ranging from pharmacological therapies that modulate bone remodeling to lifestyle modifications that enhance bone strength. Additionally, emerging technologies in diagnostics and personalized medicine have paved the way for more precise risk assessment and tailored treatment plans (Surís et al., 2022). This evolving landscape of clinical interventions offers new hope for reducing the incidence and impact of osteoporotic fractures, ultimately improving the quality of life for millions of individuals worldwide (Binding et al., 2019).

In recent decades, advances in basic research have provided a better understanding of the pathophysiology of osteoporosis and the mechanism by which osteoporotic fractures occur (Lowe et al., 2020). However, the main challenge in osteoporosis management is to translate these scientific findings into effective clinical interventions (bedside strategies) (Chen et al., 2022). The "bench-to-bedside" approach in the context of osteoporotic fractures aims to bridge the gap between scientific discoveries in the laboratory and its practical applications in patient care (Xie et al., 2019). One of the key aspects in the bench-to-bedside strategy for osteoporotic fractures is a deeper understanding of bone biology (Hoffmann et al., 2023). Basic research has revealed the important role of various bone cells, including osteoblasts, osteoclasts, and osteocytes, in the bone remodeling process. Osteoblasts are responsible for the formation of new bone, while osteoclasts play a role in bone resorption. Osteocytes, which are the most abundant bone cells, function as mechanoreceptors and regulators of bone metabolism. Understanding the complex interactions between these cells and the factors that influence their activity has paved the way for the development of new therapies (Yang et al., 2021).

Molecular research has identified various signaling pathways involved in bone mass regulation, including the RANKL/RANK/OPG pathway, Wnt signaling pathway, and sclerostin pathway (Park et al., 2023). These findings have led to the development of new therapeutic agents, such as denosumab (a monoclonal antibody against RANKL) and romosozumab (an anti-sclerostin antibody). The bench-to-bedside strategy involves translating these findings into clinical trials and eventually into clinical practice (Suen & Qin, 2016).

Additionally, advances in imaging techniques have allowed for more accurate evaluations of bone quality and fracture risk (Whittier et al., 2020). The development of technologies such as high-resolution peripheral quantitative computed tomography (HR-pQCT) and micro-magnetic resonance imaging (MRI) has enabled non-invasive assessment of bone microarchitecture (Walle et al., 2023). This information can be used to identify patients at high risk of fractures and to monitor response to treatment (Klose-Jensen et al., 2020).

The bench-to-bedside strategy also includes the development of biomarkers for diagnosis, prognosis, and monitoring of response to therapy(Wang et al., 2014). Laboratory research has identified various markers of bone turnover, such as N-terminal propeptide of type I collagen (P1NP) and C-terminal telopeptide of type I collagen (CTX), which can be used to assess bone formation and resorption activities. The use of these biomarkers in clinical practice can aid in the selection of appropriate therapies and the adjustment of treatment regimens (Domingueti et al., 2020).

Although there have been significant advances, there are still some challenges in translating laboratory findings into clinical practice. One of the main challenges is the heterogeneity of the population of osteoporosis patients. Basic research is often conducted on animal models or homogeneous cell populations, while patient populations are very diverse in terms of age, sex, comorbidities, and risk factors. Therefore, broader translational research is needed to ensure the effectiveness and safety of new interventions in various patient subpopulations (Khan et al., 2018).

Another challenge is the complexity of the pathophysiology of osteoporosis and fractures. Although basic research has identified many molecular pathways involved, the interactions between these pathways and the influence of external factors such as mechanical, hormonal, and environmental are still not fully understood (Jang et al., 2022). This highlights the need for a systems approach in osteoporosis research and the development of more holistic treatment strategies (Czerwiński et al., 2018). Another important aspect of the bench-to-bedside strategy is the personalization of treatment. With advances in genomics and proteomics, there is potential to develop more individualized treatment approaches based on the genetic and molecular profiles of patients. However, the translation of genomic findings into clinical practice is still a significant challenge (Jia, 2022).

Finally, the implementation of bench-to-bedside strategies for osteoporotic fractures also requires consideration of social, economic, and health policy factors. This includes increasing public awareness about osteoporosis, improving access to diagnostic and treatment services, and developing health policies that support the prevention and management of osteoporotic fractures (Feng et al., 2022). The bench-to-bedside approach in osteoporotic fracture management has resulted in significant advances in our understanding of the disease and the development of more effective prevention and treatment strategies. However, there are still many challenges that must be overcome to optimize the translation of research findings into clinical practice. Close collaboration between basic researchers, clinical researchers, and health practitioners will continue to be key in improving outcomes for patients with osteoporosis and reducing the burden of osteoporotic fractures in the community (Chang & Lee, 2019).

Osteoporotic fractures pose a significant health burden worldwide, necessitating innovative bench-to-bedside strategies for prevention and treatment. Recent advancements in molecular biology and translational research have unveiled promising interventions targeting key pathways in bone metabolism. These include novel anabolic agents that stimulate osteoblast activity, antiresorptive therapies that inhibit osteoclast function, and combination approaches that synergistically enhance bone strength. Additionally, emerging gene therapies and stem cell-based treatments show potential in regenerating bone tissue and improving fracture healing. Clinical trials are exploring the efficacy of these interventions, with a focus on personalized medicine approaches tailored to individual patient risk profiles. Concurrently, non-pharmacological strategies, such as exercise regimens and fall prevention programs, are being optimized to complement drug therapies. The gap between laboratory discoveries and clinical applications, the integration of these multifaceted approaches holds promise for reducing the incidence and impact of osteoporotic fractures, ultimately improving patient outcomes and quality of life

These novel strategies represent a multidisciplinary approach to tackling osteoporotic fractures. By combining advanced diagnostics, targeted therapeutics, and personalized interventions, the bench-to-bedside pipeline aims to significantly reduce fracture incidence and improve patient outcomes. Based on the literature, the purpose of this study is bench-to-bedside strategies for osteoporosis fractures through systematic reviews from various sources.

Numerous studies have highlighted advancements in osteoporosis management. A study by Huang et al. (2023) demonstrated the efficacy of novel pharmacological therapies like denosumab and romosozumab in reducing fracture risks. Similarly, Gregson et al. (2022) emphasized the importance of combining pharmacological treatments with non-pharmacological strategies, such as tailored exercise regimens, to enhance bone strength. Emerging technologies, such as high-resolution imaging, have further improved fracture risk assessments, providing personalized treatment approaches (Whittier et al., 2020). These findings underscore the importance of integrating advanced diagnostics with innovative therapies in addressing osteoporotic fractures.

Despite significant advancements in the field, gaps remain in understanding the long-term efficacy and safety of novel therapeutic interventions for diverse populations. Current studies often focus on homogenous groups, limiting the applicability of findings across different demographics. Additionally, while bench-to-bedside strategies have facilitated clinical applications, there is a need for research that bridges the translational gap by incorporating socio-economic and policy considerations into osteoporosis management. This study aims to address these gaps by examining a multidisciplinary approach that integrates clinical, technological, and socio-cultural factors.

The novelty of this research lies in its comprehensive approach to bridging the bench-to-bedside gap. Unlike previous studies, this work integrates advanced diagnostic tools, molecular therapies, and patient-centric strategies, focusing on personalized medicine and socio-economic challenges. The study also emphasizes innovative solutions, such as telemedicine and AI-driven risk assessments, to improve accessibility and efficiency in osteoporosis management.

The objective of this study is to develop and evaluate effective bench-to-bedside strategies for preventing and managing osteoporotic fractures. This includes assessing the role of molecular therapies, advanced diagnostics, and personalized approaches in reducing fracture incidence. The study's benefits extend to healthcare providers, policymakers, and patients by providing actionable insights to design targeted interventions. By improving understanding and application of cutting-edge strategies, this research aims to reduce the global burden of osteoporotic fractures and enhance patient outcomes.

METHOD

A systematic review on clinical interventions for preventing and treating osteoporotic fractures typically employs a rigorous methodology to synthesize and analyze existing research. The process begins with a comprehensive literature search across multiple databases, including PubMed, Cochrane Library, EMBASE, and Web of Science. Researchers use predefined search terms and Boolean operators to identify relevant studies. Throughout the process, adherence to guidelines such as PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) ensures transparency and reproducibility. The systematic review methodology aims to provide a comprehensive and unbiased summary of the current evidence on bench-to-bedside strategies for preventing and treating osteoporotic fractures, informing clinical practice and identifying areas for future research.

RESULTS AND DISCUSSION

A comprehensive discussion of bench-to-bedside strategies for osteoporosis fractures requires the examination of multiple aspects of this critical health issue. Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of the bone tissue, leading to increased bone fragility and susceptibility to fractures. The bench-to-bedside approach involves translating basic scientific research findings into practical clinical applications with the aim of improving patient outcomes and quality of life (Ke Ren, 2014).

It is essential to understand the pathophysiology of osteoporosis and the mechanisms that lead to fractures. At the cellular level, osteoporosis results from an imbalance between bone formation by osteoblasts and resorption by osteoclasts. This imbalance leads to a net loss of bone mass over time. Genetic factors, hormonal changes (particularly in postmenopausal women), nutritional deficiencies, and lifestyle factors contribute to this process. Understanding these mechanisms is crucial for the development of targeted therapies and preventive strategies. The development and refinement of diagnostic tools are among the primary bench-to-bedside strategies for osteoporotic fractures. Dual-energy X-ray absorptiometry (DXA) has long been the gold standard for diagnosing osteoporosis by measuring the bone mineral density (BMD). However, research has shown that BMD alone is not sufficient to predict fracture risk accurately. This has led to the development of sophisticated diagnostic approaches. For instance, the Fracture Risk Assessment Tool (FRAX) developed by the World Health Organization incorporates multiple risk factors along with BMD to provide a more comprehensive fracture risk assessment. Ongoing research is focused on improving the accuracy of these tools and developing new biomarkers that can better predict fracture risk. Advanced imaging techniques represent another area in which bench research is being translated into clinical practice. High-resolution peripheral quantitative computed tomography (HR-pQCT) allows for detailed assessment of bone microarchitecture, providing insights into bone quality beyond what is possible with traditional DXA scans. This technology enables clinicians to better understand the structural changes in the bone that contribute to fracture risk, potentially leading to more personalized treatment strategies. The bench-to-bedside approach has yielded several important advances in therapeutic intervention. Bisphosphonates, which inhibit osteoclast activity, were one of the first major breakthroughs in osteoporosis treatment. These drugs, developed based on basic research on bone metabolism, have been shown to significantly reduce fracture risk in clinical trials. However, the long-term use of bisphosphonates has been associated with rare but serious side effects, such as atypical femoral fractures and osteonecrosis of the jaw. This has spurred further research on optimizing dosing regimens and developing alternative treatments.

Recent bench-to-bedside successes include the development of denosumab, a monoclonal antibody that targets RANKL, a key molecule in osteoclast formation and function. By inhibiting RANKL, denosumab reduces bone resorption and increases bone density, leading to a reduction in the fracture risk. The development of denosumab exemplifies how the understanding of basic cellular mechanisms can lead to targeted therapies with a significant clinical impact.

Another promising research area is the use of anabolic agents to stimulate bone formation. Teriparatide, a recombinant parathyroid hormone, was the first anabolic agent approved for the treatment of osteoporosis. It also stimulates osteoblast activity and increases bone formation. More recently, abaloparatide, a synthetic analog of parathyroid hormone-related protein, was developed and approved for use in postmenopausal women at a high risk of fracture. These anabolic agents represent a shift in the treatment paradigm, from simply preventing bone loss to actively building new bonesones.

The bench-to-bedside approach has also led to advancements in combination therapy. Research has shown that the sequential or combined use of anabolic and anti-resorptive agents can lead to greater increases in bone density and potentially better fracture prevention than either approach alone. This has led to clinical trials exploring various combination strategies with the goal of optimizing treatment efficacy while minimizing side effects.

In addition to pharmacological interventions, bench research has provided nonpharmacological strategies for fracture prevention. Studies of bone biomechanics and the impact of physical activity on bone health have led to the development of targeted exercise programs. These programs aim to improve bone density, muscle strength, and balance, all of which contribute to reducing the fracture risk. Translating this research into practical implementable exercise regimens for different patient populations remains an active area of investigation.

Nutritional interventions represent another important aspect of the bench-to-bedside strategies. Although the importance of calcium and vitamin D for bone health has long been recognized, ongoing research is exploring the role of other nutrients and dietary patterns in osteoporosis prevention and management. For example, studies on the Mediterranean diet and its potential benefits for bone health have been translated into dietary recommendations for patients at a risk of osteoporosis fractures.

The field of regenerative medicine offers exciting possibilities for the treatment of osteoporotic fractures. Stem cell research and tissue engineering approaches are being explored as potential means to enhance bone healing and regeneration. Although still largely in the experimental stages, these approaches hold promise for improving fracture healing, particularly in patients with compromised bone quality. Personalized medicine is an emerging area in which bench research is increasingly informing clinical practice. Genetic studies have identified numerous loci that are associated with bone density and fracture risk. This knowledge is being translated into genetic tests that can help identify individuals at a high risk of osteoporosis and fractures. Furthermore, pharmacogenomic research is exploring how genetic variations affect individual responses to osteoporosis treatment, potentially allowing for more tailored therapeutic approaches.

The use of big data and artificial intelligence represents a new frontier in bench-to-bedside strategies for osteoporotic fractures. Large-scale data analysis and machine learning algorithms are employed to identify novel risk factors, predict treatment outcomes, and develop more accurate fracture risk assessment tools. These approaches have the potential to revolutionize the diagnosis, treatment, and prevention of osteoporotic fractures. Another important aspect of the bench-to-bedside approach is the development of improved fracture-healing strategies. Research on the molecular and cellular mechanisms of bone repair has led to the development of novel approaches to enhance fracture healing. These include the use of growth factors such as bone morphogenetic proteins (BMPs) to stimulate bone formation at fracture sites. Although the clinical use of BMPs has been limited by safety concerns and high costs, ongoing research is focused on developing more targeted and cost-effective approaches to enhance fracture healing.

Nanotechnology is another promising area of research, with potential applications in osteoporosis fracture prevention and treatment. Nanoparticles are being explored as delivery systems for osteoporosis drugs, potentially allowing for more targeted and efficient drug delivery to bone tissues. Additionally, nanostructured materials are being investigated for their potential to enhance bone regeneration and improve the integration of orthopedic implants. The development of novel biomaterials for orthopedic applications is another important bench-to-bedside strategy. Research on materials that can better mimic the properties of natural bone has led to the development of improved implants and scaffolds for bone regeneration. These advanced materials aim to provide better mechanical support and promote effective bone healing in patients with osteoporotic fractures.

Addressing the challenge of medication adherence is a critical aspect of translating osteoporosis treatment from bench to bedside. Despite the availability of effective therapies, many patients fail to adhere to the long-term treatment regimens. Research on the factors affecting medication adherence has led to the development of strategies to improve patient compliance, including the use of longer-acting formulations and patient education programs. The role of the gut microbiome in bone health is an emerging area of research with potential implications in osteoporosis management. Studies have shown that the gut microbiome can influence bone metabolism through various mechanisms, including regulation of nutrient absorption and modulation of the immune system. This research is being translated into clinical investigations of probiotics and other microbiome-targeted interventions as potential strategies for improving bone health and reducing fracture risks.

Telemedicine and digital health technologies are being increasingly integrated into osteoporosis care, representing another aspect of the bench-to-bedside approach. Remote monitoring technologies, smartphone applications for tracking medication adherence and physical activity, and virtual consultation platforms are being developed and implemented to improve patient care and outcomes. These technologies have the potential to enhance patient engagement, improve treatment adherence, and facilitate timely intervention to prevent fractures.

The economic burden of osteoporosis fractures is substantial and health economics research is an important component of bench-to-bedside strategies. Studies evaluating the cost-effectiveness of various diagnostic and treatment approaches are informing clinical guidelines and health-policy decisions. This study helps ensure that limited healthcare resources are allocated efficiently to maximize the impact on fracture prevention and patient outcomes. Addressing the health disparities in osteoporosis care is another crucial aspect of bench-to-bedside strategies. Research has shown significant disparities in osteoporosis screening, diagnosis, and treatment across demographic groups. Translating this knowledge into targeted interventions and policy changes aims to improve access to care and reduce the burden of osteoporotic fractures in underserved populations.

The development of novel drug delivery systems represents another important bench-to-bedside strategy for treating osteoporotic fractures. Traditional oral bisphosphonates, while effective, are associated with poor absorption and gastrointestinal side effects. Research on alternative delivery methods, such as transdermal patches, inhalable formulations, and long-acting injectables, aims to improve drug efficacy and patient adherence. Investigating the role of mechanical loading in bone health has led to the development of novel nonpharmacological interventions. Low-magnitude, high-frequency vibration therapy is one such approach that has shown promise in preclinical studies, and is currently being evaluated in clinical trials. This therapy aims to mimic the beneficial effects of physical activity on the bone, potentially offering an alternative or complementary approach to traditional exercise programs, particularly for patients with limited mobility.

The intersection of osteoporosis and other chronic diseases is an important area of bench-to-bedside research. Conditions such as diabetes, chronic kidney disease, and certain autoimmune disorders can significantly affect bone health and fracture risk. Understanding these complex interactions is crucial for developing comprehensive treatment strategies to address both osteoporosis and comorbid conditions. Advances in molecular imaging have provided new insights into bone metabolism and fracture healing. Positron emission tomography (PET) with novel radiotracers can provide dynamic information about bone turnover and metabolism, potentially allowing for the earlier detection of changes in bone quality and more precise monitoring of treatment response. Translating these advanced imaging techniques into clinical practice could significantly enhance our ability to assess fracture risks and guide treatment decisions.

The role of epigenetics in osteoporosis is an emerging area of research, with potential implications for both diagnosis and treatment. Epigenetic modifications such as DNA methylation and histone modifications can influence gene expression without altering the underlying DNA sequence. Understanding how these epigenetic changes affect bone metabolism may lead to the development of novel biomarkers for fracture risk and new therapeutic targets for osteoporosis treatment. Addressing the challenge of sarcopenia, or age-related loss of muscle mass and function, is increasingly being recognized as an important component of comprehensive osteoporosis management. The close relationship between muscle and bone health has led to the concept of "osteosarcopenia," highlighting the need for integrated approaches to maintain both bone and muscle strength. Translating this research into clinical practice involves developing combined interventions that target both muscles and bones, potentially including specialized exercise programs, nutritional strategies, and pharmacological approaches.

The development of novel imaging biomarkers for bone quality is another important bench-to-bedside strategy. Although BMD remains an important measure, it does not capture all aspects of bone strength. Advanced imaging techniques, such as magnetic resonance imaging (MRI) and spectral computed tomography (CT), are being explored for their ability to assess bone microarchitecture, material properties, and other factors that contribute to the overall bone quality. Translating these techniques into clinical practice could provide a more comprehensive assessment of fracture risk and guide personalized treatment approaches. In conclusion, the bench-to-bedside approach to osteoporosis fractures encompasses a wide range of strategies, from basic scientific research to clinical applications. These strategies aim to improve our understanding of the disease process, enhance the diagnostic capabilities, develop more effective treatments, and implement better preventive measures. The ultimate goal is to reduce the incidence of osteoporotic fractures, improve patient outcomes, and enhance the quality of life of patients affected by this condition. As research continues to advance, the integration of multiple approaches – pharmacological, non-pharmacological, and technological – will be crucial for addressing the complex challenges of osteoporosis fractures. The ongoing translation of scientific discoveries into clinical practice holds great promise for improving the management of osteoporosis and for reducing the burden of fractures on individuals and healthcare systems worldwide.

CONCLUSION

Bench-to-bedside strategies for osteoporosis fractures have resulted in substantial advances in the understanding, prevention, and management of this condition. The integration of basic scientific discoveries with clinical applications has resulted in better diagnostic tools, more effective therapies, and improved treatment models. However, ongoing efforts are needed to address the remaining challenges and further improve outcomes for patients with osteoporosis. A focus on personalization approaches, improved patient adherence, and broader implementation of proven fracture prevention strategies are likely to be key areas for future research and innovation in this area.

REFERENCES

Abtahi, S., Driessen, J. H. M., Burden, A. M., Souverein, P. C., Van Den Bergh, J. P., Van Staa, T. P., Boonen, A., & De Vries, F. (2022). Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink. *Rheumatology (United Kingdom)*, *61*(4). https://doi.org/10.1093/rheumatology/keab548

Binding, C., Bjerring Olesen, J., Abrahamsen, B., Staerk, L., Gislason, G., & Nissen Bonde, A. (2019). Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. *Journal of the American College of Cardiology*, *74*(17). https://doi.org/10.1016/j.jacc.2019.08.1025

Chang, S. W., & Lee, H. C. (2019). Vitamin D and health - The missing vitamin in humans. In *Pediatrics and Neonatology* (Vol. 60, Issue 3). https://doi.org/10.1016/j.pedneo.2019.04.007

Chen, X., Hu, Y., Geng, Z., & Su, J. (2022). The "Three in One" Bone Repair Strategy for Osteoporotic Fractures. In *Frontiers in Endocrinology* (Vol. 13). https://doi.org/10.3389/fendo.2022.910602

Czerwiński, E., Czubak, J., Synder, M., Warzecha, M., & Berwecka, M. (2018). Contemporary management of osteoporotic fractures. In *Ortopedia Traumatologia Rehabilitacja* (Vol. 20, Issue 2). https://doi.org/10.5604/01.3001.0011.7665

Domingueti, C. B., Castilho, D. A. Q., de Oliveira, C. E., Janini, J. B. M., González-Arriagada, W. A., Salo, T., Coletta, R. D., & Paranaíba, L. M. R. (2020). Eukaryotic translation elongation factor 1δ, N-terminal propeptide of type I collagen and cancer-associated fibroblasts are prognostic markers of oral squamous cell carcinoma patients. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, *130*(6). https://doi.org/10.1016/j.oooo.2020.09.003

Feng, F., Chen, M., Wang, X., Zhang, H., Nie, H., & Tang, H. (2022). Translation of a spinal bone cement product from bench to bedside. *Bioactive Materials*, *10*. https://doi.org/10.1016/j.bioactmat.2021.08.011

Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., McCloskey, E., Moss, K., Parker, J., Paskins, Z., Poole, K., Reid, D. M., Stone, M., Thomson, J., Vine, N., & Compston, J. (2022). UK clinical guideline for the prevention and treatment of osteoporosis. *Archives of Osteoporosis*, *17*(1). https://doi.org/10.1007/s11657-022-01061-5

Hoffmann, I., Kohl, M., von Stengel, S., Jakob, F., Kerschan-Schindl, K., Lange, U., Peters, S., Schoene, D., Sieber, C., Thomasius, F., Bischoff-Ferrari, H. A., Uder, M., & Kemmler, W. (2023). Exercise and the prevention of major osteoporotic fractures in adults: a systematic review and meta-analysis with special emphasis on intensity progression and study duration. In *Osteoporosis International* (Vol. 34, Issue 1). https://doi.org/10.1007/s00198-022-06592-8

Huang, C. F., Chen, J. F., Reid, I. R., Chan, W. P., Ebeling, P. R., Langdahl, B., Tu, S. Te, Matsumoto, T., Chan, D. C., Chung, Y. S., Chen, F. P., Lewiecki, E. M., Tsai, K. S., Yang, R. Sen, Ang, S. Bin, Huang, K. E., Chang, Y. F., Chen, C. H., Lee, J. K., … Wu, C. H. (2023). Asia–pacific consensus on osteoporotic fracture prevention in postmenopausal women with low bone mass or osteoporosis but no fragility fractures. *Journal of the Formosan Medical Association*, *122*. https://doi.org/10.1016/j.jfma.2023.01.013

Jang, H. D., Kim, E. H., Lee, J. C., Choi, S. W., Kim, H. S., Cha, J. S., & Shin, B. J. (2022). Management of Osteoporotic Vertebral Fracture: Review Update 2022. *Asian Spine Journal*, *16*(6). https://doi.org/10.31616/asj.2022.0441

Jia, H. (2022). Metagenomics from bench to bedside and from bedside to bench. In *Investigating Human Diseases with the Microbiome*. https://doi.org/10.1016/b978-0-323-91369-0.00006-6

Ke Ren, A. D. (2014). Drug Delivery Strategies for Treating Osteoporosis. *Orthopedic & Muscular System*, *s2*(01). https://doi.org/10.4172/2161-0533.s2-003

Khan, A. Z., Rames, R. D., & Miller, A. N. (2018). Clinical Management of Osteoporotic Fractures. In *Current Osteoporosis Reports* (Vol. 16, Issue 3). https://doi.org/10.1007/s11914-018-0443-y

Klose-Jensen, R., Tse, J. J., Keller, K. K., Barnabe, C., Burghardt, A. J., Finzel, S., Tam, L. S., Hauge, E. M., Stok, K. S., & Manske, S. L. (2020). High-Resolution Peripheral Quantitative Computed Tomography for Bone Evaluation in Inflammatory Rheumatic Disease. *Frontiers in Medicine*, *7*. https://doi.org/10.3389/fmed.2020.00337

Lowe, K. E., Mansfield, K. E., Delmestri, A., Smeeth, L., Roberts, A., Abuabara, K., Prieto-Alhambra, D., & Langan, S. M. (2020). Atopic eczema and fracture risk in adults: A population-based cohort study. *Journal of Allergy and Clinical Immunology*, *145*(2). https://doi.org/10.1016/j.jaci.2019.09.015

Park, J. H., Park, M. S., Kim, H. J., Lee, H., Kim, J. W., & Song, T. J. (2023). Better oral hygiene is associated with a reduced risk of osteoporotic fracture: a nationwide cohort study. *Frontiers in Endocrinology*, *14*. https://doi.org/10.3389/fendo.2023.1253903

Riggs BL, & Melton LJ III. (1995). The worldwide problem of osteoporosis: insights afforded by epidemiology. *Bone*, *17*, 505S-511S.

Suen, P. K., & Qin, L. (2016). Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review. In *Journal of Orthopaedic Translation* (Vol. 4). https://doi.org/10.1016/j.jot.2015.08.004

Sulima, A. N., Bulyuk, V. V., & Mitrofanova, O. A. (2023). POSTMENOPAUSAL OSTEOPOROSIS. In *Akusherstvo i Ginekologiya (Russian Federation)* (Vol. 2023, Issue 9). https://doi.org/10.18565/aig.2023.103

Surís, X., Vela, E., Clèries, M., Pueyo-Sánchez, M. J., Llargués, E., & Larrosa, M. (2022). Epidemiology of major osteoporotic fractures: a population-based analysis in Catalonia, Spain. *Archives of Osteoporosis*, *17*(1). https://doi.org/10.1007/s11657-022-01081-1

Walle, M., Whittier, D. E., Schenk, D., Atkins, P. R., Blauth, M., Zysset, P., Lippuner, K., Müller, R., & Collins, C. J. (2023). Precision of bone mechanoregulation assessment in humans using longitudinal high-resolution peripheral quantitative computed tomography in vivo. *Bone*, *172*. https://doi.org/10.1016/j.bone.2023.116780

Wang, C., Zhou, Y. L., Cai, H., Cheng, X. Q., Zhang, W., Kang, W. Y., Qin, X. Z., Duan, M. H., Han, H. J., Cao, X. X., Zhou, D. Bin, & Li, J. (2014). Markedly elevated serum total N-terminal propeptide of type I collagen is a novel marker for the diagnosis and follow up of patients with POEMS syndrome. In *Haematologica* (Vol. 99, Issue 6). https://doi.org/10.3324/haematol.2013.102962

Whittier, D. E., Boyd, S. K., Burghardt, A. J., Paccou, J., Ghasem-Zadeh, A., Chapurlat, R., Engelke, K., & Bouxsein, M. L. (2020). Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography. *Osteoporosis International*, *31*(9). https://doi.org/10.1007/s00198-020-05438-5

Xie, Y., Zhang, L., Xiong, Q., Gao, Y., Ge, W., & Tang, P. (2019). Bench-to-bedside strategies for osteoporotic fracture: From osteoimmunology to mechanosensation. In *Bone Research* (Vol. 7, Issue 1). https://doi.org/10.1038/s41413-019-0066-7

Yang, Z., Zhang, W., Ren, X., Tu, C., & Li, Z. (2021). Exosomes: A Friend or Foe for Osteoporotic Fracture? In *Frontiers in Endocrinology* (Vol. 12). https://doi.org/10.3389/fendo.2021.679914